RxDoctor Payments DataLook up a doctor →

Viran Holden, MD

Medical Oncology · Monett, MONPI 1912049362

Payments from drug & device makers

$875,299in general payments, 2019–2025

Across 466 payments — averaging $1878.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$463K
  • AbbVie$211K
  • Beigene, Ltd.$123K
  • GSK$22K
  • Eli Lilly$11K
  • Pfizer$10K
  • plus $36K from 49 others
$1,206in research payments, 2019–2025

Across 1 payment — averaging $1205.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen49$463,008
AbbVie81$211,105
Beigene, Ltd.6$122,786
GSK9$22,162
Eli Lilly2$10,748
Pfizer16$9,767
Boehringer Ingelheim2$7,420
Beigene USA, Inc.4$5,797
Novartis22$3,723
Boehringer Ingelheim Pharma GmbH & Co.kg5$2,650
Array Biopharma Inc4$2,437
Karyopharm Therapeutics Inc.5$2,320
Bayer6$1,727
Boehringer Ingelheim International GmbH1$1,443
E.r. Squibb & Sons, L.L.C.71$1,237
Daiichi Sankyo Inc.7$1,234
Merck15$1,059
Gilead(2 entities)10$464
Bristol Myers Squibb27$453
Eisai Inc.20$401
AstraZeneca8$400
Johnson & Johnson17$399
Incyte Corporation10$354
Stemline Therapeutics Inc.7$270
Sanofi-aventis U.S. LLC2$191
Sobi, Inc4$184
Pharmacyclics LLC, An Abbvie Company2$136
Sanofi7$124
Tempus AI, Inc2$109
Seagen Inc.1$100
Puma Biotechnology, Inc.1$94
Epizyme, Inc.1$92
Lilly USA, LLC4$76
Beone Medicines USA, Inc.3$69
Exelixis Inc.3$67
Takeda Pharmaceuticals U.S.A., Inc.3$65
Jazz Pharmaceuticals Inc.3$62
Kyowa Kirin, Inc.3$57
AVEO Pharmaceuticals, Inc.2$56
Genentech, Inc.1$50
Regeneron Healthcare Solutions, Inc.2$44
Dendreon Pharmaceuticals LLC2$42
Astellas Pharma US Inc2$41
Medtronic1$39
Pharmaessentia USA Corporation2$37
Genentech USA, Inc.2$34
Pharmacosmos Therapeutics Inc.1$21
Ipsen Biopharmaceuticals, Inc1$19
Spectrum Pharmaceuticals Inc.1$19
Avyxa Pharma, LLC1$18
Organon1$18
Octapharma USA, Inc.1$18
ADC Therapeutics America, Inc.1$18
Servier Pharmaceuticals LLC1$17
Adaptive Biotechnologies Corporation1$16

How this compares

$875,299 in reported general payments places this provider in the 65th percentile of 144 medical oncology providers in Missouri.

See all medical oncology providers in Missouri →

Medicare billing

Part B allowed, 2024
$4,366,517
Medicare patients
309
Services billed
154,858

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Monett

See the full list for Missouri →

Where these figures come from

Is this you, or does something look wrong? →